Tedor Pharma

Tedor Pharma is a private, revenue-generating CDMO headquartered in Cumberland, Rhode Island, with a state-of-the-art facility in Princeton, New Jersey. The company leverages over 20 years of collective experience to offer flexible, phase-appropriate development and GMP manufacturing services for solid oral dosage forms, with particular capabilities in handling controlled substances (DEA Schedules II-V) and complex APIs. Tedor serves biotech and pharmaceutical innovators, aiming to accelerate their path from IND through NDA/ANDA to commercial launch with a strong regulatory track record.

Integrated CDMO services for complex solid oral dosage forms, including expertise in formulation development (immediate/modified/extended release, pellets, multi-layer), process optimization, and GMP manufacturing for high-potency APIs, poorly soluble drugs, multi-API products, and DEA Schedule II-V controlled substances, supported by comprehensive analytical development.

Tedor competes in a crowded CDMO market against large global players (e.g., Lonza, Catalent) and numerous niche specialists. Its differentiation lies in its focused expertise on complex solid doses and controlled substances, its US-based facility, and its end-to-end service model tailored for small and virtual biotechs.